Precision active pharmaceutical ingredients are the goal

被引:0
|
作者
Miller, Andrew D. [1 ,2 ]
机构
[1] Kings Coll London, Inst Pharmaceut Sci, Franklin Wilkins Bldg,Waterloo Campus, London SE1 9NH, England
[2] KP Therapeut Ltd, 86 Deansgate, Manchester M3 2ER, Lancs, England
关键词
antisense peptides; chemical biology; chemistry of stress; complementary peptides; diadenosine polyphosphates; dinucleoside polyphosphates; molecular chaperones; precision active pharmaceutical ingredients; precision medicine; synthetic biology; thioether fatty acids; TRANSFER-RNA SYNTHETASE; MITOCHONDRIAL MALATE-DEHYDROGENASE; CHAPERONIN; 60; GROEL; PROTEIN; 47; HSP47; ESCHERICHIA-COLI; DIADENOSINE; 5'; 5'''-P-1; P-4-TETRAPHOSPHATE; CPN60; DINUCLEOSIDE POLYPHOSPHATES; CYTOKINE INTERLEUKIN-1; MOLECULAR CHAPERONES;
D O I
10.4155/fmc-2016-0046
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Understanding and exploiting molecular mechanisms in biology is central to chemical biology. Chemical biology studies of biological macromolecules are now in a perfect continuum with molecular level and nanomolecular level mechanistic studies involving whole organisms. The potential opportunity presented by such studies is the design and creation of genuine precision active pharmaceutical ingredients (APIs; including DNA, siRNA, smaller-molecule bioactives) that demonstrate exceptional levels of disease target-specificity and selectivity. This article covers the best of my personal and collaborative academic research work using an organic chemistry and chemical biology approach towards understanding biological molecular recognition processes, work that appears to be leading to the generation of novel precision APIs with genuine potential for the treatments of major chronic diseases that afflict globally.
引用
收藏
页码:1209 / 1238
页数:30
相关论文
共 50 条
  • [1] Polymorphism of active pharmaceutical ingredients
    Karpinski, PH
    CHEMICAL ENGINEERING & TECHNOLOGY, 2006, 29 (02) : 233 - 237
  • [2] Prequalification of active pharmaceutical ingredients
    WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS, 2015, 992 : 37 - 37
  • [3] Prequalification of active pharmaceutical ingredients
    WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS, 2013, 981 : 29 - 29
  • [4] Enabling precision manufacturing of active pharmaceutical ingredients: workflow for seeded cooling continuous crystallisations
    Brown, Cameron J.
    McGlone, Thomas
    Yerdelen, Stephanie
    Srirambhatla, Vijay
    Mabbott, Fraser
    Gurung, Rajesh
    Briuglia, Maria L.
    Ahmed, Bilal
    Polyzois, Hector
    McGinty, John
    Perciballi, Francesca
    Fysikopoulos, Dimitris
    MacFhionnghaile, Pol
    Siddique, Humera
    Raval, Vishal
    Harrington, Tomas S.
    Vassileiou, Antony D.
    Robertson, Murray
    Prasad, Elke
    Johnston, Andrea
    Johnston, Blair
    Nordon, Alison
    Srai, Jagjit S.
    Halbert, Gavin
    ter Horst, Joop H.
    Price, Chris J.
    Rielly, Chris D.
    Sefcik, Jan
    Florence, Alastair J.
    MOLECULAR SYSTEMS DESIGN & ENGINEERING, 2018, 3 (03): : 518 - 549
  • [6] The revival of cyclodextrins as active pharmaceutical ingredients
    Kfoury, Miriana
    Lichtfouse, Eric
    Fourmentin, Sophie
    ENVIRONMENTAL CHEMISTRY LETTERS, 2025, 23 (01) : 1 - 6
  • [7] Manufacturing peptides as active pharmaceutical ingredients
    Zompra, Aikaterini A.
    Galanis, Athanassios S.
    Werbitzky, Oleg
    Albericio, Fernando
    FUTURE MEDICINAL CHEMISTRY, 2009, 1 (02) : 361 - 377
  • [8] Active pharmaceutical ingredients are big business
    Stoker, A
    TCE, 2002, (732): : 38 - 39
  • [9] Ionic Liquids as Active Pharmaceutical Ingredients
    Ferraz, Ricardo
    Branco, Luis C.
    Prudencio, Cristina
    Noronha, Joao Paulo
    Petrovski, Zeljko
    CHEMMEDCHEM, 2011, 6 (06) : 975 - 985
  • [10] Active pharmaceutical ingredients and osteonecrosis of the jaw
    Orvosi Osztaly
    ORVOSI HETILAP, 2020, 161 (51) : 2176 - 2176